Get started
Work

Supplementary Figure S3 from The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions

Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figure S3 shows the doubling time of cells that were treated with seribantumab or afatinib.
DOI: 10.1158/1078-0432.22480898.v1
Authors: Igor Odintsov, Allan J.W. Lui, Whitney J. Sisso, Eric Gladstone, Zebing Liu, Lukas Delasos, Renate I. Kurth, Exequiel M. Sisso, Morana Vojnic, Inna Khodos, Marissa S. Mattar, Elisa de Stanchina, Shawn M. Leland, Marc Ladanyi, Romel Somwar
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
OpenAlex ID: W4361939293
Cites:
Cited by:
Related to: 10